Ripamonti, D., Comi, L., Valenti, D., Cargnelutti, A., Cossu, M., Poloni, A., et al. (2026). Reasons for discontinuation of single-tablet regimen rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF) in the era of 2nd-generation INSTIs. In Abstracts from the 18th Italian Conference on AIDS and Antiviral Research (pp.59-59) [10.1136/sextrans-icar-2026.58].

Reasons for discontinuation of single-tablet regimen rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF) in the era of 2nd-generation INSTIs

Cargnelutti, A;Lapadula, G;Mezzadri, L;Bonfanti, P;
2026

abstract
HIV
English
ICAR 18th Italian Conference on AIDS and Antiviral Research - May 20 to 22, 2026
2026
Abstracts from the 18th Italian Conference on AIDS and Antiviral Research
2026
102
S2
59
59
OC67
none
Ripamonti, D., Comi, L., Valenti, D., Cargnelutti, A., Cossu, M., Poloni, A., et al. (2026). Reasons for discontinuation of single-tablet regimen rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF) in the era of 2nd-generation INSTIs. In Abstracts from the 18th Italian Conference on AIDS and Antiviral Research (pp.59-59) [10.1136/sextrans-icar-2026.58].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/612711
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
Social impact